EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Epigral Ltd reported its highest-ever quarterly revenue of ₹736 crore in Q4FY26, up 17% YoY from ₹631 crore in Q4FY25. PAT for the quarter stood at ₹82 crore. On a sequential basis, revenue grew 22% versus Q3FY26 (₹603 crore), EBITDA margin improved sharply to 23% from 17% in Q3FY26, and PAT surged 109% to ₹82 crore from ₹39 crore in Q3FY26. Full-year FY2026 revenue was ₹2,542 crore, down 1% due to a 4% drop in sales volume, with EBITDA at ₹567 crore (22% margin). ROCE declined to 16% from 25% in FY2025 due to lower utilization and higher raw material costs. The Board proposed a final dividend of ₹5 per share (50% on face value). Capex of ₹394 crore was spent during the year, with expansions to CPVC (150,000 TPA), Epichlorohydrin (100,000 TPA), and Wind Solar Hybrid (38.14 MW) all on schedule. Net Debt/EBITDA was 0.9x.
Strong sequential recovery in Q4 with margin expansion signals operational normalisation. The dividend offer and expansion pipeline are positive, but the full-year revenue decline and elevated leverage warrant monitoring.